Writedowns and US decline hit Dr Reddy's third quarter

Dr Reddy’s Laboratories reported a loss of Rs5.2 billion ($112 million) for the third quarter ended December 31st, 2009, hit by writedowns in its German business, Betapharm, and a decline in revenues from the US. Total revenues for the period fell by 6% to Rs17.3 billion.

More from Neurological

More from Therapeutic Category